<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04441697</url>
  </required_header>
  <id_info>
    <org_study_id>2020PI085</org_study_id>
    <nct_id>NCT04441697</nct_id>
  </id_info>
  <brief_title>Sleepiness in Parkinson's Patients With Continuous Dopaminergic Delivery Device or Deep Brain Stimulation</brief_title>
  <official_title>Monitoring of Sleepiness in Patients With Parkinson's Disease Before and During Treatment With Continuous Dopaminergic Delivery Device or Deep Brain Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleepiness is frequent in parkinsonian patients, increasing with the duration of disease. By
      patients with motor fluctuations, continuous dopaminergic delivery devices or deep brain
      stimulation are justified to improve the motor prognosis. Antiparkinsonian treatments,
      especially dopaminergic agonists, may worsen the sleepiness and thus affect the quality of
      life. We aimed to monitor sleepiness in parkinsonian patients before and during treatment
      with continous dopaminergic delivery device or deep brain stimulation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean sleep latency</measure>
    <time_frame>before continuous antiparkinsonian treatment</time_frame>
    <description>Algebric mean (in minutes) of the sleep latency for the four experimental naps</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean sleep latency</measure>
    <time_frame>6 months after continuous antiparkinsonian treatment</time_frame>
    <description>Algebric mean (in minutes) of the sleep latency for the four experimental naps</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean sleep latency</measure>
    <time_frame>12 months after continous antiparkinsonian treatment</time_frame>
    <description>Algebric mean (in minutes) of the sleep latency for the four experimental naps</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>continuous apomorphine delivery</arm_group_label>
    <description>apomorphine, subcutaneous administration, continuous delivery during 8 to 24 hours/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>continous levodopa/carbidopa delivery</arm_group_label>
    <description>levodopa/carbidopa monohydrate, jejunal administration, continuous delivery during 8 to 24 hours/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>deep brain stimulation</arm_group_label>
    <description>bilateral subthalamic electrical stimulation, intracranial neurosurgical electrodes, individual electrical parameters settings</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Multiple sleep latency tests</intervention_name>
    <description>We measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. We also perform a nocturnal polysomnography prior to the tests for a better interpretation.</description>
    <arm_group_label>continous levodopa/carbidopa delivery</arm_group_label>
    <arm_group_label>continuous apomorphine delivery</arm_group_label>
    <arm_group_label>deep brain stimulation</arm_group_label>
    <other_name>Polysomnography</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All the patients refered to the expert Parkinson Center of the Nancy University Hospital,
        with the diagnosis of Parkinson's disease at the stage of motor fluctuations, and indicated
        for a continuous dopaminergic delivery device or deep brain stimulation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with Parkinson's disease and motor fluctuations

          -  and indicated for a continuous dopaminergic delivery device or deep brain stimulation

        Exclusion Criteria:

          -  age &lt; 18 years

          -  refusal for the continuous dopaminergic delivery device or deep brain stimulation

          -  wake-stimulating drugs intake

          -  refusal to participate

          -  legal protection

          -  uncontrolled sleep apnea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>El Mehdi Siaghy</last_name>
    <role>Study Chair</role>
    <affiliation>Research and Innovation Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas Carpentier</last_name>
    <phone>0033383858585</phone>
    <email>n.carpentier@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nancy University Hospital</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Carpentier</last_name>
      <email>n.carpentier@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>continous dopaminergic delivery device</keyword>
  <keyword>deep brain stimulation</keyword>
  <keyword>sleepiness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

